Susan Billings | Resilience

As the biopharma market transitions from generalized treatments to complex, highly tailored modalities, manufacturing infrastructure must adapt in lockstep to keep pace. In this live segment from BIO 2026 in San Diego, we visit with Susan Billings, Chief Commercial Officer at Resilience.

Bringing over two decades of end-to-end industry experience to the table, Susan shares a comprehensive, high-level look at the operational changes reshaping drug commercialization.

Susan discusses why "connection" remains the foundational value of global bio conventions and maps out the critical intersection where advanced clinical trends meet modern supply chain security.